1,25(OH)2D3对非酒精性脂肪性肝病肠道菌群及免疫调节的研究进展  

Research progress of 1,25(OH)2D3 on gut microbiota and immune regulation of nonalcoholic fatty liver disease

作　　者：黄红洽 李校天[2] HUANG Hongqia;LI Xiaotian(Department of Clinical Medicine,Hebei University of Engineering,Handan 056000;Department of Gastroenterology,Affiliated Hospital of Hebei University of Engineering,China)

机构地区：[1]河北工程大学临床医学院,河北邯郸056000 [2]河北工程大学附属医院消化内科

出　　处：《胃肠病学和肝病学杂志》2020年第11期1305-1308,共4页Chinese Journal of Gastroenterology and Hepatology

基　　金：河北省财政厅老年病防治研究项目(2016723)。

摘　　要：非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)是一种应激性、代谢性肝损伤,其发病率随着生活条件及方式的改变上升,全球发病率已超过30%。肝-肠轴研究证实,肠道菌群在其发病机制中发挥着至关重要的作用。有研究表明,1,25(OH)2D3可通过调节肠道菌群结构和免疫反应发挥脂肪肝抑制作用,本文主要从影响肠道菌群和免疫调节方面进行机制阐述,探索NAFLD治疗的新思路。Nonalcoholic fatty liver disease(NAFLD)is a stress-induced,metabolic liver injury.The incidence has increased with improvement of living conditions and methods,and currently exceeds 30%.Hepato-intestinal axis studies have confirmed that the gut microbiota plays a vital role in its pathogenesis.Studies have shown that 1,25(OH)2D3 has a significant inhibitory effect on NAFLD by regulating the structure of the gut microbiota and immune response.This article mainly discussed the mechanism of gut microbiota and immune response,and explored new approaches to NAFLD.

关 键 词：1 25(OH)2D3 肠道菌群 免疫调节 抗菌肽 非酒精性脂肪性肝病 

分 类 号：R575[医药卫生—消化系统]